Develops and sells therapies for people with serious rare and ultra-rare genetic diseases, including biologic drugs, small molecules and gene therapies.
10-K for FY2025, filed Feb 18, 2026
Sells approved medicines through distributors, with product sales tied to delivery. It also receives royalties under license agreements as the related product sales occur.
10-K for FY2025, filed Feb 18, 2026The Company sells its approved products through a limited number of distributors. Under Accounting Standards Codification, or ASC, 606…View ↗
The Company utilizes certain information from its collaboration partners to record collaboration revenue, including revenue from the sale…View ↗
During the prior profit-share period, as KKC was the principal in the sale transaction with the customer, the Company recognized a pro-rata…View ↗
$673M
10-K for FY2025, filed Feb 18, 2026
$673M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Collaboration and license
|
0.0%
FY2022: 61%
|
Collaboration and license, FY2025
$0 Sources
|
|
|
Product sales
Sold outright
10-K for FY2025, filed Feb 18, 2026 |
55%
FY2022: 33%
|
Product sales, FY2025
$369M Sources
|
Sold outright |
|
Royalty
Licensed
10-K for FY2025, filed Feb 18, 2026 |
45%
FY2022: 6.0%
|
Royalty, FY2025
$304M Sources
|
Licensed |
Its customers include collaboration partners, drug wholesalers and retail pharmacy distributors; approved products are sold through a limited number of distributors. It has its own commercial organization in many markets and uses third-party distributors in smaller markets.
10-K for FY2025, filed Feb 18, 2026CustomersView ↗
The Company sells its approved products through a limited number of distributors. Under Accounting Standards Codification, or ASC, 606…View ↗
Commercialize through patient-focused global organization. We seek to commercialize our products throughout the developed world, in North…View ↗
10-K for FY2025, filed Feb 18, 2026
Our customers include collaboration partners, drug wholesalers, and retail pharmacy distributors. For the year ended December 31, 2025, 45%…View ↗
No. It lost $575M in FY2025.
10-Q for Q3 FY2026, filed Nov 4, 2026
−$118MView ↗
10-Q for Q3 FY2026, filed Nov 4, 2026
Open tableView ↗
8-K, filed Sep 2, 2026
On September 2, 2026, Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) announced results from the Phase 3 Aspire study for…View ↗
8-K, filed Aug 19, 2026
On August 19, 2026, Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) announced the U.S. Food and Drug Administration (the…View ↗
8-K, filed Aug 11, 2026
On August 7, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”) and Baylor Research Institute (“BRI”) entered into a settlement agreement…View ↗
8-K, filed Aug 4, 2026
Reaffirm 2026 financial guidance, including total revenue of $730 million to $760 million and combined R&D and SG&A expenses to be flat to…View ↗
Evkeeza's geographic reach
The earlier report described Evkeeza as approved in the U.S. and European Economic Area; the latest report also lists Brazil, Mexico and Japan.
10-K for FY2022, filed Feb 17, 2023 10-K for FY2025, filed Feb 18, 2026Evkeeza is a fully human monoclonal antibody that binds to and blocks the function of angiopoietin-like 3, or ANGPTL3, a protein that plays…View ↗
Evkeeza is a fully human monoclonal antibody administered by IV, that binds to and blocks the function of angiopoietin-like 3, or ANGPTL3…View ↗
Competes with Arrowhead Pharmaceuticals, Eli Lilly, Dicerna, Novo Nordisk, CRISPR Therapeutics, Ionis, Oak Hill Bio, Neuren Pharmaceuticals, MavriX Bio, Esteve, Orchard Therapeutics, Denali, JCR Pharma, GC Biopharma, Novel Pharma, Beam Therapeutics, Moderna, Acer Therapeutics, Arcturus Therapeutics, and Bloomsbury
10-K for FY2025, filed Feb 18, 2026With respect to Evkeeza, the current treatments for patients with HoFH involve various lipid-lowering agents to reduce serum LDL and total…View ↗
Loading...